Biotech Values

[xrymd]

PYMX: I think the two markets—Lovenox reversal and UFH reversal—have to be considered separately.

Lovenox reversal is an impressive scientific achievement; however, I’m not sure the business impetus for such a product is strong because Lovenox, unlike UFH, is not often used in medical settings where reversal is likely to be needed.

UFH reversal is potentially a big market, so the question here is: To what extent does the superior safety of PMX-60056 warrant a premium price relative to protamine (which is dirt cheap)? Unless PYMX is able to make a convincing economic case that hospitals will save money in the long run by using PMX-60056 instead of protamine, I’m not sure hospitals will readily accept the purely medical justification. Moreover, the squeezing of hospitals’ operating margins under ObamaCare might impede the commercial uptake of PMX-60056. Regards, Dew

Dew: I am starting to think that a lovenox reversal agent will garner a moderate amount of sales. I have had to cancel numerous invasive procedures due to the patient being on lovenox. This has led to patients staying in the hospital longer than need be. It seems every patient in the hospital goes on atleast mini dose lovenox for DVT prophyaxis.

UFH I'm not convinced as protamine is so cheap. Unless you give it rapidly the minor complication rate is very small. (Transient drop in blood pressure).